1 - 3 of 3 articles
Approximately 10% to 15% of women with metastatic breast cancer will develop brain metastases. Treatment options for these women remain limited, particularly at the time of central nervous system (CNS) relapse following completion of initial CNS-directed therapy. Historically, prior studies have...
Neoadjuvant endocrine therapy is safe and can be effective in many postmenopausal women with estrogen receptor positive breast cancer. There are limited data available for premenopausal women taking aromatase inhibitors in combination with estrogen suppression. Letrozole, anastrozole, and...
The androgen receptor (AR) is expressed in 70–90% of invasive breast cancers. Despite the ubiquitous expression of AR in both primary and metastatic breast cancers, the clinical significance of this hormone receptor as a prognostic/predictive marker and its functional role in tumorigenesis...
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.